• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dabigatran in ibrutinib-treated patients with atrial fibrillation and chronic lymphocytic leukemia: experience of three cases
We report the cases relating to three patients in concomitant therapy with Ibrutinib and Dabigatran.
Source: Blood Coagulation and Fibrinolysis - February 11, 2021 Category: Hematology Tags: CASE REPORTS Source Type: research

Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study.
CONCLUSIONS: Approximately 2 out of 10 hematological cancer patients experienced MI, ischemic stroke, VTE, or bleeding requiring hospital contact within 10 years. The hematological cancer cohort had higher hazards of MI, ischemic stroke, VTE, and bleeding requiring hospital contact than a general population comparison cohort. This article is protected by copyright. All rights reserved. PMID: 31054195 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 3, 2019 Category: Hematology Authors: Adelborg K, Corraini P, Darvalics B, Frederiksen H, Ording A, Horváth-Puhó E, Rørth M, Sørensen HT Tags: J Thromb Haemost Source Type: research

Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study
Conclusions. The results of this real-life study show that in unselected patients with R/R CLL the clinical activity of ibrutinib was comparable to that reported in CTs. However, a third of patients discontinued ibrutinib within 24 months from the start of treatment. An earlier introduction of ibrutinib in the treatment approach of R/R patients, a careful surveillance and management of toxicities will optimise the clinical benefits of ibrutinib in CLL patients treated in the clinical practice.DisclosuresMauro: Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Shire: Membership on...
Source: Blood - November 21, 2018 Category: Hematology Authors: Mauro, F. R., Soddu, S., Frustaci, A. M., Orsucci, L., Motta, M., Scarfo, L., Zinzani, P. L., Falzetti, F., Farina, L., Marasca, R., Cortelezzi, A., Carlo-Stella, C., Molica, S., Coscia, M., Zaja, F., Laurenti, L., de Fabritiis, P., Gaidano, G., Gobbi, M. Tags: 642. CLL: Therapy, excluding Transplantation: Poster II Source Type: research

Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders
Source: British Journal of Haematology - September 8, 2016 Category: Hematology Authors: Stephen P. Mulligan, Christopher M. Ward, David Whalley, Sarah N. Hilmer Tags: Editorial Comment Source Type: research

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study
Summary Atrial fibrillation (AF) occurs in 5–9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non‐thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%)....
Source: British Journal of Haematology - September 8, 2016 Category: Hematology Authors: Philip A. Thompson, Vincent L évy, Constantine S. Tam, Chadi Al Nawakil, François‐Xavier Goudot, Anne Quinquenel, Loic Ysebaert, Anne‐Sophie Michallet, Marie‐Sarah Dilhuydy, Eric Van Den Neste, Jehan Dupuis, Michael J. Keating, Christophe Meune, F Tags: Short Report Source Type: research

Transient ischemic attack as an unusual initial manifestation of acute promyelocytic leukemia.
Abstract Patients with acute promyelocytic leukemia (APL) are prone to both bleeding and thrombosis. Both of these have a significant impact on the morbidity and mortality of patients with this disease. Here we report a case of a 41-year-old male, who presented with transient ischemic attack (TIA) and early neurological deterioration (END) as initial manifestations prior to an ultimate diagnosis of APL. This patient had no cerebrovascular risk factors or familial cerebrovascular disease. The patient experienced an acute ischemic stroke, verified by magnetic resonance imaging (MRI), in less than 24 h after his sec...
Source: International Journal of Hematology - March 16, 2016 Category: Hematology Authors: Liu L, Yuan X Tags: Int J Hematol Source Type: research

Acute Promyelocytic Leukemia-Associated Thrombosis.
Abstract Patients with acute promyelocytic leukemia (APL) are prone to both bleeding and thrombosis. The bleeding complications are well known. In contrast, APL-associated thrombosis is relatively underappreciated. We aimed to explore the issue of APL-associated thrombosis events. In the past 20 years, 127 cases with APL were found in our hospital database. We collected their coagulation laboratory profiles, including leukemia burdens, white blood cell and platelet counts, prothrombin time, activated partial thromboplastin time, fibrinogen levels, and disseminated intravascular coagulation scores. Data were compar...
Source: Acta Haematologica - January 23, 2013 Category: Hematology Authors: Chang H, Kuo MC, Shih LY, Wu JH, Lin TL, Dunn P, Tang TC, Hung YS, Wang PN Tags: Acta Haematol Source Type: research